We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




World’s First Bloodless Blood Test to Revolutionize Heart Failure Management

By HospiMedica International staff writers
Posted on 06 Jun 2023
Print article
Image: Bloodless Blood Tests technology identifies worsening trends before a patient becomes symptomatic (Photo courtesy of GPx)
Image: Bloodless Blood Tests technology identifies worsening trends before a patient becomes symptomatic (Photo courtesy of GPx)

Blood diagnostic tests offer a valuable glimpse into a patient's overall health, especially for those with chronic conditions like heart failure. However, despite their importance, blood tests are not performed frequently enough to provide doctors with accurate, real-time information about a patient's condition between clinic visits. Blood testing can be time-consuming and costly for both patients and healthcare providers. As such, care providers often rely on less accurate health metrics, such as weight fluctuation, for patients with heart failure. Up until now, no solution has fully met the demand for accessible, precise remote monitoring of heart failure patients. Implantable pressure sensors are an option, but they are expensive, invasive, and only a few patients qualify and are willing to undergo the procedure. Now, an innovative platform uses algorithms to analyze digital biomarkers that correspond with blood biomarkers, offering insights into underlying blood diagnostics without requiring a single blood draw.

General Prognostics (GPx, Boston, MA, USA) is pioneering the potentially lifesaving Bloodless Blood Tests technology that detects deteriorating trends before a patient shows symptoms, enabling physicians to optimize treatment, stabilize the patient's condition, and possibly prevent an expensive and dangerous hospital readmission. Bloodless Blood Tests utilize artificial intelligence (AI) to calibrate digital biomarkers with blood biomarkers, providing timely, clinically significant information about the condition of heart failure patients. Algorithmic blood tests provide an easy, convenient, and cost-effective alternative to traditional blood monitoring. With GPx's Bloodless Blood Tests, communities worldwide can readily access vital blood biomarker information.

GPx's heart failure solution, CardioID, is designed for remotely monitoring advanced heart failure patients via a wearable device and an at-home blood test. CardioID is the first implant-free, needle-free remote blood monitoring solution for heart failure patients in the world. By offering real-time insights into patient blood biomarkers, CardioID can detect significant changes in a patient's condition even before symptoms emerge. Relying on the most reliable heart failure biomarker, NT-proBNP, CardioID's Bloodless Blood Test algorithms provide reliable and actionable results. Using only non-invasive digital biomarkers, CardioID identifies NT-proBNP spikes before patients show symptoms, offering physicians an opportunity to intervene and potentially avoid hospitalization.

Related Links:
GPx 

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Multilevel Self-Loading Stretcher
CARRERA XL

Print article

Channels

Surgical Techniques

view channel
Image: The multi-sensing device can be implanted into blood vessels to help physicians deliver timely treatment (Photo courtesy of IIT)

Miniaturized Implantable Multi-Sensors Device to Monitor Vessels Health

Researchers have embarked on a project to develop a multi-sensing device that can be implanted into blood vessels like peripheral veins or arteries to monitor a range of bodily parameters and overall health status.... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.